Idiopathic Anemia of Aging (IAA)

This study has been terminated.
(No subject accrual)
Sponsor:
Information provided by:
National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:
NCT00104169
First received: February 23, 2005
Last updated: August 28, 2008
Last verified: August 2008

February 23, 2005
August 28, 2008
August 2004
May 2007   (final data collection date for primary outcome measure)
Response of Anemia
Same as current
Complete list of historical versions of study NCT00104169 on ClinicalTrials.gov Archive Site
To determine if there is a beneficial effect of quality of life, cognitive function, and physical function.
Same as current
Not Provided
Not Provided
 
Idiopathic Anemia of Aging (IAA)
Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging (IAA)

The purpose of this trial is to examine whether Epoetin Alfa, a hormone stimulating production of red blood cells, can reverse idiopathic anemia.

As individuals become older, the frequency of anemia increases. While the cause of anemia in many cases can be determined and corrected, in a number of individuals there is no correctable cause found and the patient must live with their anemia. This is known as idiopathic anemia, and can have serious consequences for the individual. Numerous studies have demonstrated that anemia is associated with loss of energy and stamina, causing individuals to decrease their activities, which adversely affects both their sense of well-being as well as their physical strength. Losses in these areas are associated with the clinical manifestations of frailty.

The current pilot study will examine whether or not administration of Epoetin Alfa, a hormone stimulating production of red blood cells, can reverse this type of anemia. We will examine the consequences of reversing the anemia in terms of physical strength and function, cardiovascular function and sense of well-being and mental function.

In this study, individuals with anemia will be treated for six months with Epoetin Alfa following the correction of their anemia and measurements done to evaluate physical strength, performance, cardiac, mental and kidney function. At the end of treatment, individuals will be followed for an additional six months to determine whether the anemia recurs and physical function decreases.

Participation in this study is voluntary. All testing and medication received are free to the participant.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Primary Purpose: Treatment
  • Anemia
  • Aging
Drug: Epoetin Alfa
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
0
May 2007
May 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 70 years of age or older
  • Diagnosed with anemia
  • Hemoglobin level less than or equal to 11
  • Able to perform most activities of daily living without restriction

Exclusion Criteria:

  • History of serious heart, liver or kidney disease
  • Cancer treated within the last year except for skin cancer (excluding melanoma)
  • Problems with your immune system
  • Received Epoetin Alfa within the last year
Both
70 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00104169
AG0014
Not Provided
Not Provided
National Institute on Aging (NIA)
Not Provided
Principal Investigator: William Ershler, MD NIA, NIH
National Institute on Aging (NIA)
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP